Premium
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-02 | Ms. Julie S. CookeChief HR Officer | -11,97k | 1,89M | Automatic Disposition | 157,62 - 158,59 | 22,37k | -34,86% |
| 2026-06-02 | Ms. Julie S. CookeChief HR Officer | -24,97k | 1,85M | Derivative Exercise and Sale | 81,49 - 157,62 | 22,37k | - |
| 2026-06-02 | Dr. Sanjay KeswaniChief Medical Officer | 1,48k | 0,00 | Derivative Exercise and Retained Stock | - | 1,48k | - |
| 2026-06-02 | Dr. Sanjay KeswaniChief Medical Officer | -1,73k | 268,34k | Derivative Exercise and Sale | 154,84 | 1,48k | - |
| 2026-06-01 | Dr. Jude OnyiaChief Scientific Officer | -11,00k | 830,57k | Derivative Exercise and Sale | 84,74 - 160,25 | 25,85k | - |
| 2026-05-29 | Dr. Ingrid DelaetChief Regulatory Officer | -2,26k | 175,66k | Derivative Exercise and Sale | 79,02 - 156,71 | 16,23k | - |
| 2026-05-27 | Dr. Jude OnyiaChief Scientific Officer | -11,00k | 778,73k | Derivative Exercise and Sale | 84,74 - 155,53 | 25,85k | - |
| 2026-05-26 | Mr. David Warren BoyerChief Corporate Affairs Officer | -3,89k | 609,02k | Automatic Disposition | 156,64 | 7,80k | -33,27% |
| 2026-05-21 | Dr. Stephen A. SherwinIndependent Director | 3,32k | 0,00 | Derivative Exercise and Retained Stock | - | 15,86k | 26,46% |
| 2026-05-21 | Dr. William H. RastetterIndependent Chairman of the Board | 3,32k | 0,00 | Derivative Exercise and Retained Stock | - | 43,68k | 8,22% |
| 2026-05-21 | Ms. Shalini SharpIndependent Director | 1,66k | 0,00 | Derivative Exercise and Retained Stock | - | 4,09k | 68,30% |
| 2026-05-21 | Mr. Richard F. PopsIndependent Director | 3,32k | 0,00 | Derivative Exercise and Retained Stock | - | 37,80k | 9,62% |
| 2026-05-21 | Ms. Christine Ann PoonIndependent Director | 3,32k | 0,00 | Derivative Exercise and Retained Stock | - | 4,75k | 231,22% |
| 2026-05-21 | Mr. George J. MorrowIndependent Director | 3,32k | 0,00 | Derivative Exercise and Retained Stock | - | 10,39k | 46,94% |
| 2026-05-21 | Ms. Leslie V. NorwalkIndependent Director | 1,66k | 0,00 | Derivative Exercise and Retained Stock | - | 4,09k | 68,30% |
| 2026-05-21 | Mr. Gary A. LyonsIndependent Director | 1,66k | 0,00 | Derivative Exercise and Retained Stock | - | 122,14k | 1,38% |
| 2026-05-21 | Ms. Johanna MercierIndependent Director | 3,32k | 0,00 | Derivative Exercise and Retained Stock | - | 6,85k | 93,86% |
| 2026-05-19 | Dr. Kevin C. GormanDirector | -205,09k | 22,78M | Derivative Exercise and Sale | 43,24 - 154,33 | 511,29k | - |
| 2026-05-19 | Dr. Kevin C. GormanDirector | -40,00k | 6,17M | Automatic Disposition | 154,33 | 511,29k | -7,26% |
| 2026-05-15 | Mr. Richard F. PopsIndependent Director | -15,00k | 1,65M | Derivative Exercise and Sale | 47,89 - 157,65 | 34,48k | - |
| 2026-05-12 | Ms. Leslie V. NorwalkIndependent Director | -3,81k | 590,60k | Automatic Disposition | 155,01 | 2,43k | -61,07% |
| 2026-03-04 | Mr. Matthew C. AbernethyCFO | -2,25k | 0,00 | Other Disposition | - | 42,81k | -4,99% |
| 2026-02-20 | Dr. Jude OnyiaChief Scientific Officer | -3,11k | 0,00 | Other Disposition | - | 25,67k | -10,81% |
| 2026-02-12 | Mr. David Warren BoyerChief Corporate Affairs Officer | 2,28k | 0,00 | Derivative Exercise and Retained Stock | - | 11,58k | 24,49% |
| 2026-02-12 | Mr. David Warren BoyerChief Corporate Affairs Officer | -2,67k | 331,02k | Derivative Exercise and Sale | 123,10 - 124,12 | 11,58k | - |
| 2026-02-13 | Mr. David Warren BoyerChief Corporate Affairs Officer | -5,38k | 667,52k | Sale to Issuer | 124,12 | 11,58k | -31,71% |
| 2026-02-12 | Mr. Matthew C. AbernethyCFO | 3,19k | 0,00 | Derivative Exercise and Retained Stock | - | 44,88k | 7,66% |
| 2026-02-12 | Mr. Matthew C. AbernethyCFO | -3,75k | 463,78k | Derivative Exercise and Sale | 123,10 - 124,12 | 44,88k | - |
| 2026-02-13 | Mr. Matthew C. AbernethyCFO | -5,38k | 667,52k | Sale to Issuer | 124,12 | 44,88k | -10,70% |
| 2026-02-12 | Mr. Kyle W. GanoPresident, CEO & Director | 4,47k | 0,00 | Derivative Exercise and Retained Stock | - | 150,82k | 3,06% |
| 2026-02-12 | Mr. Kyle W. GanoPresident, CEO & Director | -5,24k | 648,06k | Derivative Exercise and Sale | 123,10 - 124,12 | 150,82k | - |
| 2026-02-13 | Mr. Kyle W. GanoPresident, CEO & Director | -5,38k | 667,52k | Sale to Issuer | 124,12 | 150,82k | -3,44% |
| 2026-02-12 | Mr. Eric S. BenevichChief Commercial Officer | 2,79k | 0,00 | Derivative Exercise and Retained Stock | - | 63,19k | 4,61% |
| 2026-02-12 | Mr. Eric S. BenevichChief Commercial Officer | -3,26k | 404,02k | Derivative Exercise and Sale | 123,10 - 124,12 | 63,19k | - |
| 2026-02-13 | Mr. Eric S. BenevichChief Commercial Officer | -8,96k | 1,11M | Sale to Issuer | 124,12 | 63,19k | -12,42% |
| 2026-02-12 | Dr. Jude OnyiaChief Scientific Officer | 3,62k | 0,00 | Derivative Exercise and Retained Stock | - | 28,78k | 14,40% |
| 2026-02-12 | Dr. Jude OnyiaChief Scientific Officer | -4,34k | 537,72k | Derivative Exercise and Sale | 123,10 - 124,12 | 28,78k | - |
| 2026-02-13 | Dr. Jude OnyiaChief Scientific Officer | -10,76k | 1,33M | Sale to Issuer | 124,12 | 28,78k | -27,20% |
| 2026-02-12 | Mr. Darin M. LippoldtChief Legal Officer & Corporate Secretary | 2,71k | 0,00 | Derivative Exercise and Retained Stock | - | 54,73k | 5,21% |
| 2026-02-12 | Mr. Darin M. LippoldtChief Legal Officer & Corporate Secretary | -3,18k | 393,72k | Derivative Exercise and Sale | 123,10 - 124,12 | 54,73k | - |
| 2026-02-13 | Mr. Darin M. LippoldtChief Legal Officer & Corporate Secretary | -5,38k | 667,52k | Sale to Issuer | 124,12 | 54,73k | -8,95% |
| 2026-02-13 | Mr. Darin M. LippoldtChief Legal Officer & Corporate Secretary | -365,00 | 0,00 | Other Disposition | - | 54,73k | -0,66% |
| 2026-02-12 | Ms. Julie S. CookeChief HR Officer | 1,98k | 0,00 | Derivative Exercise and Retained Stock | - | 34,17k | 6,14% |
| 2026-02-12 | Ms. Julie S. CookeChief HR Officer | -2,32k | 287,19k | Derivative Exercise and Sale | 123,10 - 124,12 | 34,17k | - |
| 2026-02-13 | Ms. Julie S. CookeChief HR Officer | -5,38k | 667,52k | Sale to Issuer | 124,12 | 34,17k | -13,60% |
| 2026-02-13 | Dr. Kevin C. GormanDirector | 5,06k | 0,00 | Derivative Exercise and Retained Stock | - | 551,29k | 0,93% |
| 2026-02-13 | Dr. Kevin C. GormanDirector | -5,93k | 735,41k | Derivative Exercise and Sale | 124,12 | 551,29k | - |
| 2026-02-13 | Dr. Kevin C. GormanDirector | -34,38k | 4,27M | Sale to Issuer | 124,12 | 551,29k | -5,87% |
| 2026-02-12 | Dr. Ingrid DelaetChief Regulatory Officer | 1,99k | 0,00 | Derivative Exercise and Retained Stock | - | 16,23k | 13,97% |
| 2026-02-12 | Dr. Ingrid DelaetChief Regulatory Officer | -2,37k | 293,39k | Derivative Exercise and Sale | 123,10 - 124,12 | 16,23k | - |
| 2026-02-13 | Dr. Ingrid DelaetChief Regulatory Officer | -10,76k | 1,33M | Sale to Issuer | 124,12 | 16,23k | -39,86% |
| 2026-01-31 | Mr. David Warren BoyerChief Corporate Affairs Officer | 907,00 | 0,00 | Derivative Exercise and Retained Stock | - | 4,71k | 23,83% |
| 2026-01-31 | Mr. David Warren BoyerChief Corporate Affairs Officer | -1,19k | 161,78k | Derivative Exercise and Sale | 136,06 | 4,71k | - |
| 2026-01-31 | Mr. Eric S. BenevichChief Commercial Officer | 1,00k | 0,00 | Derivative Exercise and Retained Stock | - | 52,76k | 1,94% |
| 2026-01-31 | Mr. Eric S. BenevichChief Commercial Officer | -1,29k | 175,79k | Derivative Exercise and Sale | 136,06 | 52,76k | - |
| 2026-01-31 | Mr. Matthew C. AbernethyCFO | 1,07k | 0,00 | Derivative Exercise and Retained Stock | - | 37,10k | 2,97% |
| 2026-01-31 | Mr. Matthew C. AbernethyCFO | -1,37k | 186,13k | Derivative Exercise and Sale | 136,06 | 37,10k | - |
| 2026-01-31 | Ms. Julie S. CookeChief HR Officer | 744,00 | 0,00 | Derivative Exercise and Retained Stock | - | 27,60k | 2,77% |
| 2026-01-31 | Ms. Julie S. CookeChief HR Officer | -997,00 | 135,65k | Derivative Exercise and Sale | 136,06 | 27,60k | - |
| 2026-01-31 | Dr. Ingrid DelaetChief Regulatory Officer | 326,00 | 0,00 | Derivative Exercise and Retained Stock | - | 5,06k | 6,89% |
| 2026-01-31 | Dr. Ingrid DelaetChief Regulatory Officer | -475,00 | 64,63k | Derivative Exercise and Sale | 136,06 | 5,06k | - |
| 2026-01-31 | Mr. Kyle W. GanoPresident, CEO & Director | 1,35k | 0,00 | Derivative Exercise and Retained Stock | - | 141,75k | 0,96% |
| 2026-01-31 | Mr. Kyle W. GanoPresident, CEO & Director | -1,58k | 214,97k | Derivative Exercise and Sale | 136,06 | 141,75k | - |
| 2026-01-31 | Dr. Kevin C. GormanDirector | 2,30k | 0,00 | Derivative Exercise and Retained Stock | - | 516,89k | 0,45% |
| 2026-01-31 | Dr. Kevin C. GormanDirector | -2,85k | 387,09k | Derivative Exercise and Sale | 136,06 | 516,89k | - |
| 2026-01-31 | Mr. Darin M. LippoldtChief Legal Officer & Corporate Secretary | 1,04k | 0,00 | Derivative Exercise and Retained Stock | - | 47,79k | 2,22% |
| 2026-01-31 | Mr. Darin M. LippoldtChief Legal Officer & Corporate Secretary | -1,34k | 181,64k | Derivative Exercise and Sale | 136,06 | 47,79k | - |
| 2026-01-31 | Dr. Jude OnyiaChief Scientific Officer | 96,00 | 0,00 | Derivative Exercise and Retained Stock | - | 15,98k | 0,60% |
| 2026-01-31 | Dr. Jude OnyiaChief Scientific Officer | -142,00 | 19,32k | Derivative Exercise and Sale | 136,06 | 15,98k | - |
| 2026-01-16 | Mr. Kyle W. GanoPresident, CEO & Director | -36,40k | 3,52M | Derivative Exercise and Sale | 35,99 - 132,71 | 140,41k | - |
| 2025-11-28 | Mr. Eric S. BenevichChief Commercial Officer | 12,83k | 461,75k | Derivative Exercise and Retained Stock | 35,99 | 51,75k | 32,96% |
| 2026-01-08 | Mr. Darin M. LippoldtChief Legal Officer & Corporate Secretary | 3,35k | 120,53k | Derivative Exercise and Retained Stock | 35,99 | 46,75k | 7,72% |
| 2025-12-15 | Ms. Leslie V. NorwalkIndependent Director | 3,81k | 351,85k | Derivative Exercise and Retained Stock | 92,35 | 6,24k | 156,85% |
| 2025-12-15 | Ms. Leslie V. NorwalkIndependent Director | -6,19k | 386,81k | Derivative Exercise and Sale | 84,95 - 155,09 | 6,24k | - |
| 2025-12-08 | Mr. Darin M. LippoldtChief Legal Officer & Corporate Secretary | -4,38k | 509,40k | Derivative Exercise and Sale | 43,24 - 159,65 | 43,41k | - |
| 2025-12-03 | Mr. Gary A. LyonsIndependent Director | -15,00k | 1,57M | Derivative Exercise and Sale | 47,89 - 152,61 | 120,48k | - |
| 2025-11-29 | Dr. Jude OnyiaChief Scientific Officer | 2,18k | 0,00 | Derivative Exercise and Retained Stock | - | 15,88k | 15,89% |
| 2025-11-29 | Dr. Jude OnyiaChief Scientific Officer | -2,25k | 342,06k | Derivative Exercise and Sale | 152,16 | 15,88k | - |
| 2025-11-25 | Mr. George J. MorrowIndependent Director | -15,00k | 1,43M | Derivative Exercise and Sale | 47,89 - 143,37 | 7,07k | - |
| 2025-11-05 | Dr. William H. RastetterIndependent Chairman of the Board | -18,00k | 1,87M | Derivative Exercise and Sale | 47,89 - 151,82 | 40,36k | - |
| 2025-11-01 | Mr. Kyle W. GanoPresident, CEO & Director | 313,00 | 0,00 | Derivative Exercise and Retained Stock | - | 140,41k | 0,22% |
| 2025-11-01 | Mr. Kyle W. GanoPresident, CEO & Director | -300,00 | 42,59k | Derivative Exercise and Sale | 141,97 | 140,41k | - |
| 2025-09-03 | Dr. Jude OnyiaChief Scientific Officer | -1,47k | 0,00 | Other Disposition | - | 13,70k | -9,69% |
| 2025-09-02 | Dr. Stephen A. SherwinIndependent Director | -1 000,00 | 0,00 | Other Disposition | - | 12,54k | -7,38% |
| 2025-08-07 | Dr. Kevin C. GormanDirector | -106,32k | 9,61M | Derivative Exercise and Sale | 35,99 - 126,41 | 514,60k | - |
| 2025-08-05 | Dr. Jude OnyiaChief Scientific Officer | -3,12k | 0,00 | Other Disposition | - | 15,17k | -17,04% |
| 2025-07-10 | Dr. Ingrid DelaetChief Regulatory Officer | -457,00 | 25,58k | Derivative Exercise and Sale | 79,02 - 135,00 | 4,73k | - |
| 2025-07-09 | Dr. Jude OnyiaChief Scientific Officer | -59,82k | 2,73M | Derivative Exercise and Sale | 84,74 - 130,46 | 18,29k | - |
| 2025-07-02 | Dr. Jude OnyiaChief Scientific Officer | -20,36k | 924,26k | Derivative Exercise and Sale | 84,74 - 130,13 | 18,29k | - |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
